{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:00:22Z","timestamp":1787979622948,"version":"build-2784847793"},"reference-count":20,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"DOI":"10.1182\/bloodadvances.2025016695","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T20:49:39Z","timestamp":1752785379000},"page":"4806-4809","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-0514","authenticated-orcid":false,"given":"Asis","family":"Shrestha","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Internal Medicine, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Internal Medicine, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishee","family":"Bag","sequence":"additional","affiliation":[{"name":"2Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Internal Medicine, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al-Hadidi","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Internal Medicine, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Internal Medicine, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-6745","authenticated-orcid":false,"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[{"name":"4Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-3085","authenticated-orcid":false,"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[{"name":"2Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Internal Medicine, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"3","key":"2025101410264032700_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/ejh.12907","article-title":"Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register","volume":"99","author":"Nahi","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2025101410264032700_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clml.2024.10.014","article-title":"Clinical characteristics and survival outcomes of patients with primary and secondary plasma cell leukemia according to the 2021 definition: a single center retrospective study","volume":"25","author":"Shalaby","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2025101410264032700_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025101410264032700_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025101410264032700_bib5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/10428194.2018.1473574","article-title":"Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients","volume":"60","author":"Jurczyszyn","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025101410264032700_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2021.01.002","article-title":"Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia","volume":"21","author":"Parrondo","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025101410264032700_bib7","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/S2152-2650(24)01666-5","article-title":"MM-336 long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"24","author":"Garfall","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025101410264032700_bib8","doi-asserted-by":"crossref","first-page":"901266","DOI":"10.3389\/fonc.2022.901266","article-title":"Case report: plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy","volume":"12","author":"Deng","year":"2022","journal-title":"Front Oncol"},{"issue":"21","key":"2025101410264032700_bib9","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2025101410264032700_bib10","doi-asserted-by":"crossref","first-page":"e70192","DOI":"10.1002\/cam4.70192","article-title":"Poor outcome despite modern treatments: a retrospective study of 99 patients with primary and secondary plasma cell leukemia","volume":"13","author":"Tessier","year":"2024","journal-title":"Cancer Med"},{"issue":"3","key":"2025101410264032700_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.leu.2403647","article-title":"Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment","volume":"19","author":"P\u00e9rez-Andr\u00e9s","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"2025101410264032700_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence for a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"issue":"12","key":"2025101410264032700_bib13","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"van de Donk","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2025101410264032700_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.11.016","article-title":"Absolute lymphocyte count prior to lymphodepletion impacts outcomes in multiple myeloma patients treated with chimeric antigen receptor T cells","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2025101410264032700_bib15","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"key":"2025101410264032700_bib16","doi-asserted-by":"crossref","first-page":"1083053","DOI":"10.3389\/fonc.2023.1083053","article-title":"High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics","volume":"13","author":"Xia","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"2025101410264032700_bib17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/16078454.2021.1948208","article-title":"Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma","volume":"26","author":"Han","year":"2021","journal-title":"Hematology"},{"issue":"1","key":"2025101410264032700_bib18","doi-asserted-by":"crossref","first-page":"2338604","DOI":"10.1080\/07853890.2024.2338604","article-title":"Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis","volume":"56","author":"Li","year":"2024","journal-title":"Ann Med"},{"issue":"6","key":"2025101410264032700_bib19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"2025101410264032700_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4806\/2413707\/blooda_adv-2025-016695-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4806\/2413707\/blooda_adv-2025-016695-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:39:19Z","timestamp":1760452759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/4806\/546235\/The-efficacy-of-teclistamab-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":20,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016695","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,9,24]]}}}